214 related articles for article (PubMed ID: 25544610)
1. Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
Vasudevan D; Takeuchi H; Johar SS; Majerus E; Haltiwanger RS
Curr Biol; 2015 Feb; 25(3):286-295. PubMed ID: 25544610
[TBL] [Abstract][Full Text] [Related]
2. Analyzing the Effects of O-Fucosylation on Secretion of ADAMTS Proteins Using Cell-Based Assays.
Berardinelli SJ; Haltiwanger RS
Methods Mol Biol; 2020; 2043():25-43. PubMed ID: 31463900
[TBL] [Abstract][Full Text] [Related]
3. ADAMTS9 and ADAMTS20 are differentially affected by loss of B3GLCT in mouse model of Peters plus syndrome.
Holdener BC; Percival CJ; Grady RC; Cameron DC; Berardinelli SJ; Zhang A; Neupane S; Takeuchi M; Jimenez-Vega JC; Uddin SMZ; Komatsu DE; Honkanen R; Dubail J; Apte SS; Sato T; Narimatsu H; McClain SA; Haltiwanger RS
Hum Mol Genet; 2019 Dec; 28(24):4053-4066. PubMed ID: 31600785
[TBL] [Abstract][Full Text] [Related]
4. Peters plus syndrome mutations affect the function and stability of human β1,3-glucosyltransferase.
Zhang A; Venkat A; Taujale R; Mull JL; Ito A; Kannan N; Haltiwanger RS
J Biol Chem; 2021 Jul; 297(1):100843. PubMed ID: 34058199
[TBL] [Abstract][Full Text] [Related]
5. O-fucosylation stabilizes the TSR3 motif in thrombospondin-1 by interacting with nearby amino acids and protecting a disulfide bond.
Berardinelli SJ; Eletsky A; Valero-González J; Ito A; Manjunath R; Hurtado-Guerrero R; Prestegard JH; Woods RJ; Haltiwanger RS
J Biol Chem; 2022 Jun; 298(6):102047. PubMed ID: 35597280
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of zebrafish orthologs of the human Beta 3-Glucosyltransferase B3GLCT gene mutated in Peters Plus Syndrome.
Weh E; Takeuchi H; Muheisen S; Haltiwanger RS; Semina EV
PLoS One; 2017; 12(9):e0184903. PubMed ID: 28926587
[TBL] [Abstract][Full Text] [Related]
7. High-Throughput miRFluR Platform Identifies miRNA Regulating B3GLCT That Predict Peters' Plus Syndrome Phenotype, Supporting the miRNA Proxy Hypothesis.
Thu CT; Chung JY; Dhawan D; Vaiana CA; Mahal LK
ACS Chem Biol; 2021 Oct; 16(10):1900-1907. PubMed ID: 34085516
[TBL] [Abstract][Full Text] [Related]
8. O-fucosylation of thrombospondin type I repeats is dispensable for trafficking thrombospondin 1 to platelet secretory granules.
Berardinelli SJ; Sillato AR; Grady RC; Neupane S; Ito A; Haltiwanger RS; Holdener BC
Glycobiology; 2023 May; 33(4):301-310. PubMed ID: 36721988
[TBL] [Abstract][Full Text] [Related]
9. Contribution of a Novel
Totoń-Żurańska J; Kapusta P; Rybak-Krzyszkowska M; Lorenc K; Machlowska J; Skalniak A; Filipek E; Pawlik D; Wołkow PP
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795264
[TBL] [Abstract][Full Text] [Related]
10.
Zhang A; Berardinelli SJ; Leonhard-Melief C; Vasudevan D; Liu TW; Taibi A; Giannone S; Apte SS; Holdener BC; Haltiwanger RS
J Biol Chem; 2020 Nov; 295(46):15742-15753. PubMed ID: 32913123
[No Abstract] [Full Text] [Related]
11. Hydrocephalus in mouse B3glct mutants is likely caused by defects in multiple B3GLCT substrates in ependymal cells and subcommissural organ.
Neupane S; Goto J; Berardinelli SJ; Ito A; Haltiwanger RS; Holdener BC
Glycobiology; 2021 Sep; 31(8):988-1004. PubMed ID: 33909046
[TBL] [Abstract][Full Text] [Related]
12. Peters plus syndrome and Chorioretinal findings associated with B3GLCT gene mutation - a case report.
Wang YE; Ramirez DA; Chang TC; Berrocal A
BMC Ophthalmol; 2020 Mar; 20(1):118. PubMed ID: 32204707
[TBL] [Abstract][Full Text] [Related]
13. Two distinct pathways for O-fucosylation of epidermal growth factor-like or thrombospondin type 1 repeats.
Luo Y; Nita-Lazar A; Haltiwanger RS
J Biol Chem; 2006 Apr; 281(14):9385-92. PubMed ID: 16464858
[TBL] [Abstract][Full Text] [Related]
14. Impaired ADAMTS9 secretion: A potential mechanism for eye defects in Peters Plus Syndrome.
Dubail J; Vasudevan D; Wang LW; Earp SE; Jenkins MW; Haltiwanger RS; Apte SS
Sci Rep; 2016 Sep; 6():33974. PubMed ID: 27687499
[TBL] [Abstract][Full Text] [Related]
15. Novel B3GALTL mutations in classic Peters plus syndrome and lack of mutations in a large cohort of patients with similar phenotypes.
Weh E; Reis LM; Tyler RC; Bick D; Rhead WJ; Wallace S; McGregor TL; Dills SK; Chao MC; Murray JC; Semina EV
Clin Genet; 2014 Aug; 86(2):142-8. PubMed ID: 23889335
[TBL] [Abstract][Full Text] [Related]
16. 6-alkynyl fucose is a bioorthogonal analog for O-fucosylation of epidermal growth factor-like repeats and thrombospondin type-1 repeats by protein O-fucosyltransferases 1 and 2.
Al-Shareffi E; Chaubard JL; Leonhard-Melief C; Wang SK; Wong CH; Haltiwanger RS
Glycobiology; 2013 Feb; 23(2):188-98. PubMed ID: 23045360
[TBL] [Abstract][Full Text] [Related]
17. Peters'-plus syndrome is a congenital disorder of glycosylation caused by a defect in the beta1,3-glucosyltransferase that modifies thrombospondin type 1 repeats.
Heinonen TY; Maki M
Ann Med; 2009; 41(1):2-10. PubMed ID: 18720094
[TBL] [Abstract][Full Text] [Related]
18. Ocular Phenotype of Peters-Plus Syndrome.
Shah PR; Chauhan B; Chu CT; Kofler J; Nischal KK
Cornea; 2022 Feb; 41(2):219-223. PubMed ID: 34629439
[TBL] [Abstract][Full Text] [Related]
19. First functional analysis of a novel splicing mutation in the B3GALTL gene by an ex vivo approach in Tunisian patients with typical Peters plus syndrome.
Ben Mahmoud A; Siala O; Mansour RB; Driss F; Baklouti-Gargouri S; Mkaouar-Rebai E; Belguith N; Fakhfakh F
Gene; 2013 Dec; 532(1):13-7. PubMed ID: 23954224
[TBL] [Abstract][Full Text] [Related]
20.
Takeuchi H; Yu H; Hao H; Takeuchi M; Ito A; Li H; Haltiwanger RS
J Biol Chem; 2017 Sep; 292(38):15964-15973. PubMed ID: 28729422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
